Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -197% Improvement Relative Risk Ventilation -94% Recovery time 32% Recovery time (b) 19% primary Hospitalization time 15% Ivermectin  Shahbaznejad et al.  LATE TREATMENT  DB RCT Is late treatment with ivermectin beneficial for COVID-19? Double-blind RCT 69 patients in Iran Faster recovery (p=0.048) and shorter hospitalization (p=0.016) Shahbaznejad et al., Clinical Therapeu.., Jan 2021 Favors ivermectin Favors control

Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial

Shahbaznejad et al., Clinical Therapeutics, doi:10.1016/j.clinthera.2021.04.007 (partial results available 1/19), IRCT20111224008507N3
Jan 2021  
  Source   PDF   All   Meta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
*, now known with p < 0.00000000001 from 102 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
RCT in Iran showing shorter time to recovery and shorter hospitalization time with ivermectin. There were no adverse effects. There was one death in the treatment group, the patient was in critical condition at baseline and died within 24 hours of admission. Also see and the author response
This is the 15th of 49 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000038.
This is the 34th of 102 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 560 quintillion).
risk of death, 197.1% higher, RR 2.97, p = 1.00, treatment 1 of 35 (2.9%), control 0 of 34 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), patient died within 24 hours of admission.
risk of mechanical ventilation, 94.3% higher, RR 1.94, p = 1.00, treatment 2 of 35 (5.7%), control 1 of 34 (2.9%).
recovery time, 31.6% lower, relative time 0.68, p = 0.048, treatment 35, control 34, duration of dsypnea.
recovery time, 19.2% lower, relative time 0.81, p = 0.02, treatment 35, control 34, duration of all symptoms, primary outcome.
hospitalization time, 15.5% lower, relative time 0.85, p = 0.02, treatment 35, control 34.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shahbaznejad et al., 19 Jan 2021, Double Blind Randomized Controlled Trial, Iran, peer-reviewed, 8 authors, average treatment delay 6.29 days, dosage 200μg/kg single dose, trial IRCT20111224008507N3. Contact:
This PaperIvermectinAll
Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial
Leila Shahbaznejad, MD Alireza Davoudi, MD; Gohar Gohar Eslami, PharmD; John S Markowitz, Mohammad Reza Navaeifar, MD Fatemeh Hosseinzadeh, Faeze Sadat Movahedi, MSc Mohammad Sadegh Rezai
Clinical Therapeutics, doi:10.1016/j.clinthera.2021.04.007
Purpose. Given the coronavirus disease-2019 (COVID-19) pandemic, there is a global urgency to discover an effective treatment against this disease. This study aimed to evaluate the effect of the widely used antiparasitic drug ivermectin on COVID-19 patient outcomes. Methods. In this randomized double-blind clinical trial, COVID-19 patients admitted to two referral tertiary hospitals of Mazandaran, north of Iran, were randomly divided into two groups of intervention and control. In addition to standard treatment for COVID-19, the intervention group received a single weight-based dose (0.2 mg/kg) of ivermectin. Demographic, clinical, laboratory and imaging data of participants were recorded at baseline. Patients were daily assessed for clinical complaints and disease progression. The primary clinical outcome measures were duration of hospital stay, fever, dyspnea, cough, and overall clinical improvement. Findings. Sixty-nine patients with the mean age of 47.6±22.2 and 45.2±23.1 years participated in intervention and control groups, respectively (p=0.6). Nineteen patients (54%) in the ivermectin group and 18(53%) in control group were male (p=0.9). The mean duration of dyspnea was 2.4±1.7 days in the ivermectin and 3.7±2.1 days in the control group (p=0.02). Also, persistent cough lasted for 3.1±1.9 days in the ivermectin group compared to 4.8±2.0 days in control group (p=0.00). The mean duration of hospital stay was 6.9±3.1 vs 8.3±3.3 days for the ivermectin and control group, respectively (p=0.01). Also, the frequency of lymphopenia decreased to 14.3% in the ivermectin group and did not change in the control group (p=0.00). Implications. A single dose of ivermectin was well-tolerated in symptomatic COVID-19 patients and improved important clinical features of COVID-19 patients including dyspnea, cough, and lymphopenia. Further studies with larger sample sizes, different drug dosages, dosing intervals and durations, especially in different stages of the disease, may help understanding ivermectin's potential clinical benefits. Trial registration. The current controlled trial was registered in the Iranian Registry of Clinical Trials
Declaration of Competing Interest The authors have declared that no competing interests exist. Authors' Contributions MSR and LSh contributed to study conception and design. ARD, MSR and LSh contributed to data collection and patient sampling. FH and MRN contributed to drafting and editing the manuscript. FSM performed the statistical analysis. MSR, LSh and FH revised the manuscript. MSR and GE provided study supervision. JSM assisted in the drafting and editing the manuscript All authors read and approved the submitted manuscript. Consent for publication Written informed consent was obtained from the patients or their parents prior to manuscript submission for their personal or clinical details in addition to any identifying images to be published in this study. Ethics approval and consent to participate The ethics committee of Mazandaran University of Medical Sciences approved the study protocol (Code: IR.MAZUMS.REC.1399.057) and it was registered in the Iranian Registry of Clinical Trials (code: IRCT20111224008507N3). The patients of this manuscript have not been reported in any other submission by us or anyone else. Availability of data and material All data generated or analyzed during this study are included in this published article. For additional data, please contact the corresponding author ( Financial disclosure The authors received no specific funding for this work.
Ahmed, Karim, Ross, A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, International Journal of Infectious Diseases
Alam, Murshed, Bhiuyan, Saber, Alam et al., A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline, Journal of Bangladesh College of Physicians and Surgeons
Beigel, Tomashek, Dodd, Remdesivir for the treatment of Covid-19-preliminary report, New England Journal of Medicine
Bernheim, Mei, Huang, Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection, Radiology
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Research, doi:10.1016/j.antiviral.2020.104787
Cao, Wang, Wen, A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, New England Journal of Medicine
Chaccour, Hammann, Ramón-García, Rabinovich, Ivermectin and COVID-19: Keeping Rigor in Times of Urgency, The American Journal of Tropical Medicine and Hygiene
Chandler, Serious neurological adverse events after ivermectin-do they occur beyond the indication of onchocerciasis? The American journal of tropical medicine and hygiene
Dong, Hu, Gao, Discovering drugs to treat coronavirus disease 2019 (COVID-19), Drug Discoveries & Therapeutics
Essid, Allouche, Lazzem, Ecotoxic response of nematodes to ivermectin, a potential anti-COVID-19 drug treatment, Marine Pollution Bulletin
Fathi, Rezaei, Lymphopenia in COVID-19: Therapeutic opportunities, Cell Biology International
Gorial, Mashhadani, Sayaly, Effectiveness of ivermectin as add-on therapy in COVID-19 management
Group, Dexamethasone in hospitalized patients with Covid-19-preliminary report, New England Journal of Medicine
Gupta, Sahoo, Singh, Ivermectin: potential candidate for the treatment of Covid 19, The Brazilian Journal of Infectious Diseases
Heidary, Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, The Journal of Antibiotics
Huang, Pranata, Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis, Journal of Intensive Care
Juarez, Schcolnik-Cabrera, Dueñas-Gonzalez, The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug, American journal of cancer research
Ko, Rolain, Lee, Arguments in favour of remdesivir for treating SARS-CoV-2 infections, International journal of antimicrobial agents
Larsen, Pasalic, Hvas, Platelets in coronavirus disease
Lim, Debruin, Leider, Developing an Ethics Framework for Allocating Remdesivir in the COVID-19 Pandemic
Lin, Li, interpretation of" guidelines for the diagnosis and treatment of novel coronavirus (2019-ncov) infection by the national health commission (trial version 5), Zhonghua yi xue za zhi
Rahimzadeh, Noghabi, Elyaderani, COVID-19 infection in Iranian children: a case series of 9 patients, Journal of Pediatrics Review
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19
Rizzo, Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action, Naunyn Schmiedebergs Arch Pharmacol
Satici, Demirkol, Altunok, Performance of pneumonia severity index and CURB-65 in predicting 30-day mortality in patients with COVID-19, International Journal of Infectious Diseases
Shahbaznejad, Navaeifar, Abbaskhanian, Hosseinzadeh, Rahimzadeh et al., Clinical characteristics of 10 children with a pediatric inflammatory multisystem syndrome associated with COVID-19 in Iran, BMC pediatrics
Vallejos, Zoni, Bangher, Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial, Trials
Wang, Zhang, Du, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, The Lancet
Xie, Covassin, Fan, Association between hypoxemia and mortality in patients with COVID-19
Xu, Zhong, Deng, High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa, International journal of oral science
Zhang, Xu, Sun, Zhou, Current targeted therapeutics against COVID-19: based on first-line experience in china, Pharmacological Research
Zheng, Peng, Xu, Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis, Journal of Infection
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop